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OBJECTIVE—It has been suggested that interleukin (IL)-6 is one
of the mediators linking obesity-derived chronic inﬂammation with
insulin resistance through activation of STAT3, with subsequent
upregulation of suppressor of cytokine signaling 3 (SOCS3). We
evaluated whether peroxisome proliferator–activated receptor
(PPAR)-b/-d prevented activation of the IL-6-STAT3-SOCS3 path-
way and insulin resistance in adipocytes.
RESEARCH DESIGN AND METHODS—Adipocytes and white
adipose tissue from wild-type and PPAR-b/-d-null mice were used
to evaluate the effect of PPAR-b/-d on the IL-6-STAT3-SOCS3
pathway.
RESULTS—First, we observed that the PPAR-b/-d agonist
GW501516 prevented both IL-6–dependent reduction in insulin-
stimulated Akt phosphorylation and glucose uptake in adipocytes.
In addition, this drug treatment abolished IL-6–induced SOCS3
expression in differentiated 3T3-L1 adipocytes. This effect was
associated with the capacity of the drug to prevent IL-6–induced
STAT3 phosphorylation on Tyr705 and Ser727 residues in vitro and
in vivo. Moreover, GW501516 prevented IL-6–dependent induction
of extracellular signal–related kinase (ERK)1/2, a serine-threonine-
protein kinase involved in serine STAT3 phosphorylation. Further-
more, in white adipose tissue from PPAR-b/-d–null mice, STAT3
phosphorylation (Tyr705 and Ser727), STAT3 DNA-binding activity,
and SOCS3 protein levels were higher than in wild-type mice. Sev-
eral steps in STAT3 activation require its association with heat
shock protein 90 (Hsp90), which was prevented by GW501516
as revealed in immunoprecipitation studies. Consistent with this
ﬁnding, the STAT3-Hsp90 association was enhanced in white
adipose tissue from PPAR-b/-d–null mice compared with wild-
type mice.
CONCLUSIONS—Collectively, our ﬁndings indicate that PPAR-
b/-d activation prevents IL-6–induced STAT3 activation by inhibit-
ing ERK1/2 and preventing the STAT3-Hsp90 association, an effect
that may contribute to the prevention of cytokine-induced insulin
resistance in adipocytes. Diabetes 60:1990–1999, 2011
Accumulating evidence suggests that type 2 di-abetes is associated with a cytokine-relatedacute-phase reaction, as part of an overall inﬂa-mmatory state. Indeed, insulin resistance cor-
relates with increased acute-phase response marker levels,
including tumor necrosis factor-a (TNF-a) (1), interleukin
(IL)-1b (2), and IL-6 (3–5). Of these cytokines, IL-6 shows
a strong association with obesity in both human and ro-
dent models. Thus elevated levels of IL-6 in humans posi-
tively correlate with obesity and insulin resistance and
predict the development of type 2 diabetes (5–7), whereas
depletion of IL-6 ameliorates insulin signaling in obese
mice (8).
IL-6 signals through a transmembrane receptor complex
containing the common signal transducing receptor gly-
coprotein gp130, which activates Janus tyrosine kinases
(Jak1, Jak2, Tyk2), with subsequent Tyr705 phosphoryla-
tion of STAT3 (9–11). Phosphorylated STAT3 dimerizes
and translocates to the nucleus, where it regulates the
transcription of target genes through binding to speciﬁc
DNA-responsive elements (12). In addition to activation by
Tyr705 phosphorylation, STAT3 also requires phosphory-
lation on Ser727 to achieve maximal transcriptional activity
(13,14). Protein kinases involved in STAT3 serine phos-
phorylation include protein kinase C, Jun NH2-terminal
kinase, extracellular signal-regulated kinase (ERK), the
mitogen-activated protein kinase p38, and mammalian
target of rapamycin (mTOR) (15). Interestingly, interaction
of STAT3 with the chaperone heat shock protein 90 (Hsp90)
contributes to many steps in STAT3 activation (16).
Suppressor of cytokine signaling (SOCS) is a family of
target genes that are upregulated through IL-6–mediated
activation of STAT3. These SOCS proteins were originally
described as cytokine-induced molecules involved in a
negative feedback loop of cytokine (17) and insulin sig-
naling (18). Several studies have reported that SOCS3 can
inhibit insulin signaling (18–20) by direct interaction with
the insulin receptor and by preventing the coupling of in-
sulin receptor substrate (IRS)-1 with the insulin receptor,
thereby inhibiting IRS-1 tyrosine phosphorylation and
downstream insulin signaling (18,19). In addition, SOCS3
inhibits insulin signaling by proteasomal-mediated degra-
dation of IRS-1 (20). Thus overexpression of SOCS3 in
adipocytes inhibits insulin signal transduction (19,21),
whereas SOCS3 deﬁciency in adipocytes increases insulin-
stimulated IRS-1 phosphorylation and glucose uptake (22).
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Peroxisome proliferator–activated receptors (PPARs)
are members of the nuclear receptor superfamily of ligand-
inducible transcription factors that form heterodimers
with retinoid X receptors (RXRs) and bind to consensus
DNA sites (23). In addition, PPARs may suppress inﬂa-
mmation through diverse mechanisms, such as reduced
release of inﬂammatory factors or stabilization of repres-
sive complexes at inﬂammatory gene promoters (24–27).
Of the three PPAR isotypes found in mammals, PPAR-a
(NR1C1) (28) and PPAR-g (NR1C3) are the targets for
hypolipidemic (ﬁbrates) and antidiabetic (thiazolidine-
diones) drugs, respectively. Finally, activation of the third
isotype, PPAR-b/-d (NR1C2, called PPAR-d below), en-
hances fatty acid catabolism in adipose tissue and skeletal
muscle; therefore, it has been proposed as a potential
treatment for insulin resistance (29). Recently, it was re-
ported that agonist-activated PPAR-d interferes with IL-6–
mediated acute phase reaction in the liver by inhibiting
the transcriptional activity of STAT3 (30), although the
exact molecular mechanism involved remains unknown.
Given the prominent role of the STAT3-SOCS3 pathway in
IL-6–mediated insulin resistance in adipocytes, we ex-
plored whether PPAR-d activation by GW501516 prevented
IL-6–mediated insulin resistance in adipocytes and the
mechanisms involved. PPAR-d activation by GW501516
prevented the reduction in insulin-stimulated Akt phos-
phorylation and glucose uptake, indicating that this drug
prevents IL-6–induced insulin resistance. In addition, we
found that this drug prevented IL-6–mediated induction of
SOCS3 mRNA levels and STAT3 phosphorylation in 3T3-L1
adipocytes. Consistent with the role of PPAR-d in blocking
IL-6–induced STAT3 activity, STAT3-DNA binding activity
and STAT3 phosphorylation was higher in white adipose
tissue from PPAR-d–null mice than in wild-type mice. Our
ﬁndings also show that PPAR-d activation elicited STAT3
dissociation from Hsp90 in adipocytes, whereas the asso-
ciation of these two proteins was greatly enhanced in
white adipose tissue in PPAR-d–null mice compared with
wild-type mice. Overall, on the basis of our ﬁndings, we
suggest that PPAR-d activation can ameliorate insulin re-
sistance in adipose tissue by preventing activation of the
STAT3-SOCS3 pathway by cytokines.
RESEARCH DESIGN AND METHODS
Materials. The PPAR-d ligand GW501516 was obtained from Biomol Research
Laboratories (Plymouth Meeting, PA). Other chemicals were from Sigma
(St. Louis, MO).
Cell culture. 3T3-L1 preadipocytes [American Type Culture Collection
(ATCC)] were grown to conﬂuence in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% bovine calf serum. Two days after conﬂu-
ence (day 0), differentiation of the 3T3-L1 cells was induced in DMEM con-
taining 10% FBS, methylisobutylxanthine (500 mmol/L), dexamethasone (0.25
mmol/L), and insulin (5 mg/mL) for 48 h. The cells were then incubated in 10%
FBS/DMEM with insulin for 3 days and this was then replaced with FBS/
DMEM. Medium was changed every 2 days. Fat droplets were observed in
more than 90% of cells after day 10. Adipocytes were then incubated with 10
mmol/L GW501516 and IL-6 (10 or 100 ng/mL) for the times indicated. After
incubation, RNA and total and nuclear protein extracts were extracted from
adipocytes as described below. Inhibitors were added 30 min before in-
cubation with IL-6.
Animals. Obese male ZDF rats (ZDF/Gmi, fa/fa) and their lean littermates (fa/+
or +/+) were used. Both strains were maintained under standard light-dark cycle
(12-h light/dark cycle) and temperature (21 6 1°C) conditions and fed with
Purina 5008 chow. Male ZDF and lean rats were killed at 12 weeks of age. CD-1
male mice (12 weeks old) were treated for 48 h with vehicle (100 mL PBS-0.1%
BSA and 0.5% w/v carboxymethylcellullose medium viscosity), IL-6 (0.8 mg/g
body wt i.p.), or IL-6 plus GW501516 (one daily oral gavage of 3 mg/kg/day
GW501516 dissolved in carboxymethylcellullose). Epididymal white adipose
tissue of rats and mice was rapidly removed, frozen in liquid nitrogen, and
stored at 280°C. All procedures were conducted in accordance with the prin-
ciples and guidelines established by the University of Barcelona Bioethics
Committee, as stated in Law 5/1995, 21 July, passed by the Generalitat de
Catalunya.
The generation of PPAR-d–null mice was described previously (31). Eight
male PPAR-d–null mice and eight of their control male PPAR-d wild-type
mice were used (5 to 6 months of age). In agreement with the guidelines
speciﬁed by the veterinary ofﬁce of Lausanne (Switzerland), the mice were
housed under standard light-dark cycle (12-h light/dark cycle) and temper-
ature (21 6 1°C) conditions and fed with Provimi Kliba 3436 chow. Epidid-
ymal white adipose tissue was rapidly removed, frozen in liquid nitrogen, and
stored at 280°C.
2-Deoxy-D-[14C]glucose uptake experiment. Determination of 2-Deoxy-D-
[14C]glucose (2-DG) uptake was performed as reported elsewhere (32).
Measurements of mRNA. Levels of mRNA were assessed by RT-PCR as
previously described (33). Total RNA was isolated using the Ultraspec reagent
(Biotecx, Houston, TX). The total RNA isolated by this method is nondegraded
and free of protein and DNA contamination. The sequences of the sense and
antisense primers used for ampliﬁcation were: Socs3 (suppressor of cytokine
signaling 3) 59-TTTTCGCTGCAGAGTGACCCC-39 and 59-TGGAGGAGAGAG
GTCGGCTCA-39; early growth response (Egr-1), 59-CTTCCTCTGCCTCCCA-
GAGCC-39 and 59-TGGGAACCTGGAAACCACCCT-39, and Aprt (adenosyl
phosphoribosyl transferase), 59-GCCTCTTGGCCAGTCACCTGA-39 and 59-CCA-
GGCTCACACACTCCACCA-39. Ampliﬁcation of each gene yielded a single band
of the expected size (Socs3: 250 bp, Egr-1: 210 bp, and Aprt: 329 bp). Preliminary
experiments were carried out with various amounts of cDNA to determine
nonsaturating conditions of PCR ampliﬁcation for all the genes studied. Under
these conditions, relative quantiﬁcation of mRNA was then assessed by the RT-
PCR method used in this study (34). Radioactive bands were quantiﬁed by video-
densitometric scanning (Vilbert Lourmat Imaging). The results for the expression
of speciﬁc mRNAs are always presented relative to the expression of the control
gene (Aprt).
Isolation of nuclear extracts. Nuclear extracts were isolated as previously
described (35). Cells were scraped into 1.5 mL of cold PBS, pelleted for 10 s,
and resuspended in 400 mL cold Buffer A (10 mM HEPES [pH 7.9 at 4°C],
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF, and 5 mg/mL apro-
tinin) by ﬂicking the tube. Cells were allowed to swell on ice for 10 min and
then vortexed for 10 s. Samples were then centrifuged for 10 s, and the su-
pernatant fraction was discarded. Pellets were resuspended in 50 mL of cold
Buffer C (20 mM HEPES-KOH [pH 7.9 at 4°C], 25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 5 mg/mL apro-
tinin, and 2 mg/mL leupeptin) and incubated on ice for 20 min for high-salt
extraction. Cellular debris was removed by centrifugation for 2 min at 4°C,
and the supernatant fraction (containing DNA-binding proteins) was stored
at 280°C. Nuclear extract concentration was determined by the Bradford
method.
Electrophoretic mobility shift assay. Electrophoretic mobility shift assay
(EMSA) was performed using double-stranded oligonucleotides (Santa Cruz) for
the consensus binding site of the STAT3 nucleotide (59-GATCCTTCTGGGAA-
TTCCTAGATC-39). Oligonucleotides were labeled in the following reaction: 2
mL of oligonucleotide (1.75 pmol/mL), 2 mL 53 kinase buffer, 1 mL T4 poly-
nucleotide kinase (10 units/mL), and 2.5 mL [g-32P]ATP (3,000 Ci/mmol at
10 mCi/mL) incubated at 37°C for 2 h. The reaction was stopped by adding 90 mL
of TE buffer (10 mmol/L Tris-HCl [pH 7.4] and 1 mmol/L EDTA). To separate the
labeled probe from the unbound ATP, the reaction mixture was eluted in a Nick
column (Amersham) following the manufacturer’s instructions. Crude nuclear
protein (mg) was incubated for 10 min on ice in binding buffer (10 mmol/L Tris-
HCl [pH 8.0], 25 mmol/L KCl, 0.5 mmol/L DTT, 0.1 mmol/L EDTA [pH 8.0], 5%
glycerol, 5 mg/mL BSA, and 50 mg/mL poly[dI-dC]), in a ﬁnal volume of 15 mL.
Labeled probe (~75,000 cpm) was added, and the reaction was incubated for
30 min at 4°C. Where indicated, speciﬁc competitor oligonucleotide was added
before the labeled probe and incubated for 20 min on ice. STAT3 antibody was
added 15 min before incubation with the labeled probe at 4°C. Protein-DNA
complexes were resolved by electrophoresis at 4°C on a 5% acrylamide gel and
subjected to autoradiography.
Antibodies, immunoprecipitation, and immunoblotting. Antibodies against
total and phospho-ERK1/2 and phospho-STAT3 (Tyr705 and Ser727) were pur-
chased from Cell Signaling. Antibodies against total STAT3 and Hsp90 were
purchased from Santa Cruz.
To obtain total protein, cells and adipose tissue were homogenized in
radioimmunoprecipitation assay (RIPA) buffer (Sigma) with phosphatase
inhibitors (0.2 mmol/L phenylmethylsulfonyl ﬂuoride, 1 mmol/L sodium
orthovanadate, 5.4 mg/mL aprotinin). The homogenate was centrifuged at
16,700g for 30 min at 4°C. Protein concentration was measured by the
Bradford method.
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Whole-cell lysates and nuclear extracts were mixed with various antibodies
(as speciﬁed under RESULTS) and protein A coupled to agarose beads. Proteins
from whole-cell lysates, nuclear extracts, and immunoprecipitates were sepa-
rated by SDS-PAGE and then transferred to immobilon polyvinylidene diﬂouride
membranes (Millipore, Bedford, MA) and blotted with various antibodies (as
speciﬁed in RESULTS). Detection was achieved using the EZ-ECL chemilumi-
nescence kit (Amersham). Size of detected proteins was estimated using protein
molecular-mass standards (Invitrogen, Barcelona, Spain).
Statistical analyses. Data are presented as mean 6 SD of ﬁve separate
experiments. Signiﬁcant differences were established by one-way ANOVA,
using the GraphPad InStat program (GraphPad Software V2.03, GraphPad
Software, San Diego, CA). When signiﬁcant variations were found, the Tukey-
Kramer multiple comparisons test was applied. Differences were considered
signiﬁcant at P , 0.05.
RESULTS
PPAR-d activation restores IL-6 defects in Akt acti-
vation and glucose uptake in response to insulin. We
ﬁrst examined the effects of the PPAR-d agonist GW501516
on IL-6–induced insulin resistance, which was assessed as
the inhibition of insulin-stimulated Akt phosphorylation and
glucose uptake. Differentiated 3T3-L1 adipocytes were
stimulated with IL-6 in the absence or in the presence of
GW501516, a selective ligand for PPAR-d with a 1,000-fold
higher afﬁnity toward PPAR-d than PPAR-a and PPAR-g
(36). Exposure of adipocytes to IL-6 for 24 h caused
a reduction in insulin-stimulated Akt phosphorylation (Fig.
1A). In contrast, when cells preincubated with 10 mmol/L
GW501516 were exposed to IL-6 the inhibitory effect of this
cytokine on insulin-stimulated Akt phosphorylation was
prevented. The effect of GW501516 on insulin-stimulated
Akt phosphorylation was also observed at lower concen-
trations and the effect attained at 10 mmol/L was dependent
on PPAR-d since it was abolished by coincubation with the
PPAR-d antagonist GSK0660 (Fig. 1B). Similarly, GW501516
signiﬁcantly reversed the reduction observed in glucose
uptake in IL-6–stimulated cells (Fig. 1C). Drug treatment in
the absence of insulin did not affect the phosphorylation
status of Akt (data not shown). Thus GW501516 treatment
offered protection against a reduction in insulin re-
sponsiveness by IL-6.
PPAR-d activation inhibits IL-6–induced SOCS3
expression in 3T3-L1 adipocytes by preventing STAT3
activation. Because IL-6–induced insulin resistance in
3T3-L1 adipocytes has been attributed to SOCS3 (22), we
then examined the effect of PPAR-d activation on the
mRNA levels of the STAT3-target gene SOCS3. Differen-
tiated 3T3-L1 adipocytes were stimulated with 10 ng/mL
of IL-6 for 1 h in the absence or in the presence of
GW501516. Under these conditions, the increase in SOCS3
FIG. 1. PPAR-d activation antagonizes IL-6 action by restoring insulin responsiveness. Differentiated adipocytes were stimulated with 100 nmol/L
insulin for 30 min, with or without pretreatment with either 10 mmol/L GW501516 or 100 ng/mL IL-6 for 24 h. A: Cell lysates were subjected to
Western blot analysis for phospho-Akt(Ser473) and total Akt and b-actin. B: Different concentrations of GW501516 were assayed on insulin-
stimulated Akt-phosphorylation in cells exposed to IL-6. Indicated cells were pretreated for 30 min with 10 mmol/L GSK0660 before treatment with
GW501516. ***P < 0.001 vs. control cells stimulated with insulin; ###P < 0.001 vs. IL-6-stimulated cells in the presence of insulin. C: 2-Deoxyglucose
uptake was assessed without or with insulin. Values are means 6 SD of six independent experiments. ***P < 0.001 vs. control cells without insulin
stimulation; ###P < 0.001 vs. control cells stimulated with insulin; @P < 0.05 vs. IL-6–exposed cells.
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FIG. 2. The PPAR-d agonist GW501516 prevents IL-6–induced SOCS3 expression and STAT3 phosphorylation in 3T3-L1 adipocytes. A: Analysis of
the mRNA levels of Socs3 in serum-starved differentiated adipocytes untreated or treated with 10 mmol/L GW501516 for 24 h or 2 mmol/L
geldanamycine for 30 min before stimulation with 10 ng/mL IL-6 for 1 h. Total RNA was isolated and analyzed by RT-PCR. A representative au-
toradiogram and the quantiﬁcation normalized to the AprtmRNA levels are shown. Data are the means6 SD of ﬁve independent experiments. 3T3-
L1 adipocytes were treated with 10 mmol/L GW501516 for 24 h before stimulation with 10 ng/mL IL-6 for 24 h. Nuclear (B) or total cell extracts (C)
were subjected to Western blot analysis with phospho-STAT3 (Tyr705 and Ser727) or STAT3 antibodies (B) or phospho-ERK1/2 and ERK1/2 (C)
antibodies. D: Analysis of the mRNA levels of Egr-1 in 3T3-L1 serum-starved differentiated adipocytes untreated or treated with 10 mmol/L
GW501516 for 24 h before stimulation with 10 ng/mL IL-6 for 1 h. Total RNA was isolated and analyzed by RT-PCR. Bars are the means 6 SD of ﬁve
independent experiments. *P< 0.05; **P< 0.01; ***P< 0.001 vs. control; @P< 0.05 vs. IL-6+GW501516-exposed cells; #P< 0.05 and ###P< 0.001
vs. IL-6–stimulated cells. Dividing lines indicate grouping of images from different parts of the same gel.
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mRNA levels caused by IL-6 exposure (23-fold induction;
P , 0.001) was reduced in cells coincubated with IL-6
plus GW501516 (sevenfold induction; P , 0.001 vs. IL-6–
stimulated cells) (Fig. 2A). Furthermore, because of re-
cent reports showing suppression of IL-6 signaling through
inhibition of STAT3-Hsp90 interaction by the selective
Hsp90 inhibitor geldanamycin (16,37,38), we also evalu-
ated the effects of the latter. Geldanamycin treatment
signiﬁcantly reduced the increase in SOCS3 mRNA levels
caused by IL-6 (P , 0.05 vs. IL-6–stimulated cells). Overall,
these ﬁndings suggest that PPAR-d activation inhibits
STAT3. Dimerization, nuclear translocation, and increase
in transcriptional activity of STAT3 require its phos-
phorylation on tyrosine residue 705. In addition, STAT3
phosphorylation on Ser727 is required for its maximal
activation (13,14). When we analyzed the phosphoryla-
tion status of STAT3 we observed that IL-6 exposure in-
creased both Tyr705 and Ser727 phosphorylation, whereas
in the presence of GW501516 these changes were pre-
vented (Fig. 2B). Because IL-6 activates ERK1/2 (10), which
has been reported to be a kinase for STAT3 phosphory-
lation on Ser727 (15), and we have previously reported
that GW501516 prevents LPS-induced ERK1/2 activation
in adipocytes (36), we evaluated the effect of the PPAR-d
agonist on the activation of this kinase. IL-6 exposure
caused a slight increase in ERK1/2 phosphorylation,
whereas GW501516 strongly suppressed ERK1/2 protein
phosphorylation (Fig. 2C). Consistent with these changes,
the increase in Egr-1 mRNA levels, which has been at-
tributed to IL-6–mediated activation of ERK1/2 (10), was
abolished by GW501516 (Fig. 2D). To demonstrate the
involvement of the ERK1/2 activation in IL-6–induced
insulin resistance in adipocytes, we took advantage of
U0126, a potent and speciﬁc ERK1/2 inhibitor, which binds
to mitogen-activated protein kinase (MAPK)–ERK1/2
(MEK1/2), thereby inhibiting its catalytic activity as well
as phosphorylation of ERK1/2. Similarly to GW501516,
U0126 prevented the reduction in insulin-stimulated Akt
phosphorylation (Fig. 3A) and glucose-uptake (Fig. 3B) and
prevented the increase in STAT3 phosphorylation on Ser727
(Fig. 3C) caused by IL-6. U0126 treatment alone did not
affect the phosphorylation status of Akt (data not shown).
GW501516 prevents the increase in SOCS3 protein
levels and STAT3 activity induced by IL-6 in vivo. We
have previously reported that PPAR-d expression and
activity is reduced, whereas ERK1/2 phosphorylation is
increased in white adipose tissue from an animal model
of obesity and insulin resistance, the ZDF (fa/fa) rat
(36). In the current study we found that STAT3 phos-
phorylation at Ser727 and SOCS3 protein levels were in-
creased in white adipose tissue of ZDF rats compared
with lean animals (Fig. 4A and B). Hence, we hypothe-
sized that reduced PPAR-d activity and enhanced ERK1/2
activation may contribute to the increase in STAT3 ac-
tivity in the white adipose tissue of the ZDF rat. We then
evaluated whether GW501516 might prevent the increase
FIG. 3. ERK1/2 inhibition prevents IL-6–induced insulin resistance and STAT3 phosphorylation on Ser727. Differentiated adipocytes were stimu-
lated with 100 nmol/L insulin for 30 min, with or without pretreatment with either 10 mmol/L U0126, 10 mmol/L GW501516, or 100 ng/mL IL-6 for
24 h. A: Cell lysates were subjected to Western blot analysis for phospho-Akt(Ser473) and total Akt and b-actin. B: 2-Deoxyglucose uptake
was assessed without or with insulin. Values are means 6 SD of six independent experiments. C: Nuclear cell extracts were subjected to Western
blot analysis with phospho-STAT3 (Ser727), STAT3, or Lamin B antibodies. ***P< 0.001 vs. control cells without insulin stimulation; ##P< 0.01 vs.
control cells stimulated with insulin; @@P < 0.01 vs. IL-6–exposed cells. Dividing lines indicate grouping of images from different parts of the
same gel.
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FIG. 4. The PPAR-d agonist GW501516 prevents IL-6–induced SOCS3 expression and STAT3 phosphorylation in white adipose tissue. Phospho-
STAT3 (Ser727) and SOCS3 protein levels are increased in white adipose tissue of ZDF rats. A: Analysis of phospho-STAT3 (Ser727) and total
STAT3 by immunoblotting of nuclear or total protein extracts from white adipose tissue of lean and ZDF rats. B: Total cell extracts from white
adipose tissue of lean and ZDF rats were subjected to Western blot analysis with SOCS3 and b-actin antibodies. Mice were treated for 48 h with
vehicle, IL-6, or IL-6 plus GW501516. SOCS3 (C), phospho-STAT3 (Tyr705 and Ser727) (D), and phospho-ERK1/2 (E) protein levels. Nuclear
(phospho-STAT3-Ser727) or total cell extracts were subjected to Western blot analysis with phospho-STAT3 (Tyr705) or STAT3 antibodies or phospho-
ERK1/2 and ERK1/2 antibodies. Bars are the means6 SD of four independent experiments. ***P< 0.001; **P< 0.01 vs. control; ###P< 0.001 vs.
IL-6–treated mice. Dividing lines indicate grouping of images from different parts of the same gel.
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in STAT3-SOCS3 pathway in white adipose tissue after
IL-6 stimulation in vivo in a similar fashion as observed
in vitro. When we examined the SOCS3 protein levels in
mice exposed to IL-6 (Fig. 4C) we observed that the in-
crease caused by IL-6 treatment was prevented in those
mice treated with the PPAR-d agonist. Similarly, drug
treatment prevented the increase in the phosphorylation
status of STAT3 in both Tyr705 and Ser727 (Fig. 4D). In agree-
ment with data obtained in vitro, GW501516 inhibited the
increase in phospho-ERK1/2 levels induced by IL-6 treatment
(Fig. 4E).
Increased STAT3 activity in the white adipose tissue
of the PPAR-d–null mouse. To clearly demonstrate the
involvement of PPAR-d in the regulation of STAT3 activity in
white adipose tissue we took advantage of the PPAR-d–null
mouse. In the absence of PPAR-d, Tyr705 and Ser727 phos-
phorylation of STAT3 and SOCS3 protein levels were in-
creased compared with wild-type mice (Fig. 5A). Consistent
with these changes, the DNA-binding activity of STAT3 was
strongly increased in nuclear extracts of white adipose tis-
sue of PPAR-d–null mice compared with wild-type animals
(Fig. 5B).
PPAR-d elicits STAT3 dissociation from Hsp90. Hsp90
is thought to contribute to many steps in STAT3 activation,
such as binding to its docking sites on gp130 and sub-
sequent phosphorylation by associated JAKs, as well as
enhanced trafﬁcking of the activated cytosolic STAT3 to the
nucleus (16,37). Thus we examined whether PPAR-d sup-
pressed IL-6 signaling through inhibition of STAT3-Hsp90
interaction. This interaction was studied by using nuclear
extracts of 3T3-L1 adipocytes stimulated with IL-6 in the
presence or in the absence of GW501516 and the Hsp90
inhibitor geldanamycin, which were immunoprecipitated
with anti-Hsp90, and analyzed by Western blot (Fig. 6A). IL-6
stimulation caused an increase in the interaction of Hsp90
with STAT3, whereas in the presence of GW501516 or
geldanamycin the IL-6–induced recruitment of Hsp90 to
STAT3 was blocked. Consistent with this, the association
of STAT3 with Hsp90 was very faint in white adipose tissue
of wild-type mice but strongly increased in PPAR-d–null
mice (Fig. 6B). Overall, these ﬁndings indicate that PPAR-d
may inhibit IL-6–induced STAT3 activation by promoting
STAT3 dissociation from Hsp90.
DISCUSSION
Insulin resistance and type 2 diabetes are closely associ-
ated with low-grade chronic inﬂammation characterized
by abnormal proinﬂammatory cytokine production (39),
such as TNF-a (1) and IL-6 (4,5,21). Of these cytokines,
IL-6 plasma levels correlate more strongly with the sever-
ity of insulin resistance in insulin-resistant patients than
with TNF-a (3,6). Adipocytes play an important role in
IL-6–induced insulin resistance since adipose tissue is an
FIG. 5. The PPAR-d–null mouse shows STAT3 activation and enhanced SOCS3 protein levels in white adipose tissue. A: Cellular extracts from wild-
type (WT) or PPAR-d–null (knockout [KO]) mouse white adipose tissue were analyzed by Western blot with phospho-STAT3 (Tyr705 and Ser727),
STAT3, SOCS3, and b-actin antibodies as indicated. B: Autoradiograph of EMSA performed with a 32P-labeled STAT3 nucleotide and nuclear
protein extracts (NE). One speciﬁc complex (I), based on competition with a molar excess of unlabeled probe, is shown. An analysis performed by
incubating NE with an antibody directed against STAT3 is also shown.
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important source (40) and a major target of this cytokine.
IL-6 acts primarily by activating STAT3 and upregulating
the transcription of its target gene SOCS3, which causes
insulin resistance by interfering with insulin receptors and/
or IRS-1 (19,41–43). Our ﬁndings demonstrate that PPAR-d
activation by GW501516 prevents IL-6–induced expression
of SOCS3 in adipocytes, showing a similar effect to that
reported for the PPAR-g activators rosiglitazone (21) and
pioglitazone (44). These data suggest that PPAR-d prevents
STAT3 activation in adipocytes, which is in agreement
with a previous report showing that GW501516 prevented
IL-6–induced STAT3 activation in hepatocytes (30), although
in this latter study the molecular mechanism involved was
not elucidated. The activity of STAT3 is dependent on
its phosphorylation status. Thus STAT3 phosphorylation on
Tyr705 leads to dimerization and translocation to the nucleus,
where it regulates the transcription of its target genes (12),
whereas phosphorylation of Ser727 is required to achieve
maximal activity (13,14). Our ﬁndings show that the PPAR-d
activator GW501516 inhibits IL-6–induced STAT3 phosphor-
ylation on both residues. The increase in STAT3 phosphor-
ylation, STAT3 DNA-binding activity, and SOCS3 protein
levels in white adipose tissue from PPAR-d2null mice com-
pared with wild-type animals clearly indicates that PPAR-d
inhibits STAT3 activation in adipocytes. Interestingly, white
adipose tissue from ZDF rats showed increased STAT3
serine phosphorylation and SOCS3 protein levels. These
changes could be related to the reduction in PPAR-d ex-
pression observed in white adipose tissue of ZDF rats (36).
In addition, because overexpression of SOCS3 in adipose
tissue causes local but not systemic insulin resistance (45),
these ﬁndings suggest that the increase in SOCS3 levels in
white adipose tissue from ZDF rats might, at least, exacer-
bate insulin resistance in this tissue, thereby contributing to
the metabolic alterations observed in this animal model of
type 2 diabetes.
The prevention of IL-6–induced STAT3 activation after
PPAR-d activation might be the result of several mecha-
nisms of action. First, protein kinases responsible for STAT3
serine phosphorylation include, among others, ERK1/2 (46),
and we have previously reported that GW501516 inhibits
ERK1/2 phosphorylation in adipocytes (36). GW501516
abolished both ERK1/2 phosphorylation and the expres-
sion of Egr-1, which is upregulated after ERK1/2 activation
(10), suggesting that inhibition of this protein kinase by
PPAR-d activation might be involved in the suppression of
STAT3 Ser727 phosphorylation in IL-6–exposed cells. These
data are consistent with previous studies reporting that the
MEK/ERK inhibitor PD98059 suppresses STAT3 serine
phosphorylation, whereas STAT3 tyrosine phosphoryla-
tion was blunted by the JAK2 inhibitor AG490 (47). How-
ever, our ﬁndings also showed a reduction of STAT3 Tyr705
phosphorylation after GW501516 treatment, suggesting that
additional mechanisms were involved. This second mecha-
nism might involve a reduction in the interaction of STAT3
with Hsp90. In fact, activation of STAT3 requires its asso-
ciation with Hsp90 in many steps, including binding to its
docking sites on gp130 and subsequent phosphorylation by
associated JAKs and its translocation to the nucleus (16).
Thus it has been reported that both geldanamycin, a selec-
tive Hsp90 inhibitor, and pyrrolidine dithiocarbamate
(PDTC) inhibit STAT3 tyrosine and serine phosphorylation
and its translocation to the nucleus by reducing the asso-
ciation of STAT3 with Hsp90 (16). Our immunoprecipita-
tion studies in adipocytes exposed to IL-6 indicate that
PPAR-d activation by GW501516 dissociates Hsp90 from
STAT3, a mechanism that may prevent STAT3 activation
by phosphorylation. In agreement with this, white adipose
tissue from PPAR-d knockout mice showed enhanced
STAT3 phosphorylation and DNA-binding activity. Our
data do not explain how PPAR-d activation reduces the
physical interaction between STAT3 and Hsp90. However,
because it has been reported that PPAR-d interacts with
Hsp90 (48), it is likely that competition between PPAR-d
and STAT3 for binding to Hsp90 may reduce the availability
of this heat shock protein to interact with STAT3.
The mechanisms of action responsible for STAT3 in-
hibition by PPAR-d agonists reported here are different to
that previously reported for PPAR-g activators (49,50).
Thus ligand binding to PPAR-g promotes its dissociation
from the corepressor silencing mediator for retinoid and
thyroid hormone receptors (SMRT), which, in turn, inter-
acts with STAT3 and inhibits its transcriptional activity. It
remains a matter of further study whether PPAR-g ligands
inhibit STAT3 by promoting its dissociation from Hsp90.
However, this possibility seems unlikely since it has been
reported that, in contrast with PPAR-d and PPAR-a, PPAR-g
does not interact with Hsp90 (48). Further studies are
necessary to evaluate whether PPAR-d–mediated inhibition
of STAT3 involves enhanced interaction between SMRT and
STAT3.
It has been suggested that the proinﬂammatory cytokine
IL-6 is one of the mediators linking obesity-derived chronic
inﬂammation with insulin resistance. In addition, it has
previously been reported that STAT3 activation is required
for IL-6 inhibition of insulin signaling in hepatocytes (51)
and that the negative effect of IL-6 on insulin signaling in
adipocytes is linked to the upregulation of SOCS3 (21).
Thus we wanted to explore whether PPAR-d activation
prevented IL-6–induced insulin resistance in adipocytes. In
agreement with the reported inhibition of the STAT3-
SOCS3 by GW501516, PPAR-d activation by this drug
prevented the reduction in insulin-stimulated Akt phos-
phorylation and glucose uptake caused by IL-6 exposure.
These ﬁndings suggest that the inhibition of STAT3 and the
subsequent reduction in SOCS3 levels after PPAR-d acti-
vation in IL-6–stimulated adipocytes might contribute to-
ward preventing IL-6–induced insulin resistance. Given
that impairment of insulin resistance in adipocytes by ex-
posure to TNF-a (52) and IL-1a (53) has been largely as-
sociated with IL-6 production and SOCS3 induction, it is
likely that the effects of PPAR-d on the improvement in
insulin sensitivity can also be extended to these cytokines.
FIG. 6. PPAR-d activation dissociates the complex formed between
Hsp90 and STAT3. A: Differentiated adipocytes untreated or treated
with 10 mmol/L GW501516 for 24 h or 2 mmol/L geldanamycine for
30 min before stimulation with 10 ng/mL IL-6 for 24 h. Nuclear extracts
were immunoprecipitated (IP) with anti-Hsp90 followed by Western
blot analysis using antibodies directed against STAT3.B: Cellular extracts
from wild-type (WT) or PPAR-d–null (KO) mouse white adipose tissue
were immunoprecipitated (IP) with anti-STAT3 followed by Western blot
analysis using antibodies directed against Hsp90 or STAT3.
L. SERRANO-MARCO AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JULY 2011 1997
In summary, on the basis of our ﬁndings in adipocytes,
we suggest that PPAR-d activation prevents IL-6–induced
STAT3 activation and SOCS3 upregulation, thereby con-
tributing toward preventing the cytokine-mediated devel-
opment of insulin resistance.
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